Caffeine and Training Intensity Quantification

NCT ID: NCT06210984

Last Updated: 2024-01-18

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-01-31
• Study Completion Date: 2025-12-31

Brief Summary

The goal of this clinical trial is to learn about the effects of caffeine on exercise physiology and the subsequent quantification of athlete training zones in trained cyclists. The main questions that it aims to answer are:

• What are the effects of low and moderate doses of caffeine on exercise physiology.
• How do the effects of caffeine on exercise physiology affect the calculation of training zones.
• Do the effects of caffeine on exercise physiology differ between men and women.

Participants will complete four trials on a cycle ergometer as follows:

• Trial 1: participants will complete two incremental tests to determine the power outputs required to elicit 50-80% of maximal oxygen consumption for trials 2-4.
• Trials 2-4: participants will consume (in a randomized order) either a low (2 mg/kg) dose of caffeine, a moderate (5 mg/kg) dose of caffeine, or a placebo (maltodextrin), 45 minutes prior to to completing an incremental cycling test from 50-80% of maximal oxygen uptake.

Measures of heart rate, oxygen uptake, blood lactate, and perceived exertion will be recorded throughout all trials.

Researchers will compare the effects of exercise intensity, caffeine dose, and sex to see if they affect exercise physiology and training zone quantification.

Conditions

Caffeine

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: DOUBLE

Study Groups

Low caffeine dose

2 mg/kg dose of caffeine (in pill form)

Group Type: EXPERIMENTAL

Low caffeine dose

Intervention Type: DRUG

2 mg/kg dose of caffeine in pill form

Moderate caffeine dose

5 mg/kg dose of caffeine (in pill form)

Group Type: EXPERIMENTAL

Moderate caffeine dose

Intervention Type: DRUG

5 mg/kg dose of caffeine in pill form

Placebo

5 mg/kg dose of placebo (Maltodextrin in pill form)

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

5 mg/kg dose of maltodextrin in pill form

Interventions

Low caffeine dose

2 mg/kg dose of caffeine in pill form

Intervention Type: DRUG

Moderate caffeine dose

5 mg/kg dose of caffeine in pill form

Intervention Type: DRUG

Placebo

5 mg/kg dose of maltodextrin in pill form

Intervention Type: DRUG

Eligibility Criteria

Exclusion Criteria

-

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

St. Mary's University, Twickenham

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

Stmarys1

Identifier Type: -

Identifier Source: org_study_id